Faron, etusivu

Strategy

Faron’s strategy reflects a significant demand for novel therapies to manage symptoms and improve outcomes in challenging cases of hematologic cancers and solid tumors.

Key elements of Faron’s strategy 

Become revenue generating with data from MDS

  • Partnership(s) and first approvals

Expand by generating Proof of Concept Phase II data in new indications

  • Both in blood cancers and solid tumors

New Phase II studies will be primarily ran using funds obtained through deals and partnerships

  • A tiered approach until resources enable parallel development in multiple indications and settings at the same time

New Phase II studies will commence depending on available resources, clinical importance and market opportunity, i.e. non-competitive areas with clear unmet need

Back to top